Spark Therapeutics, Inc. (NASDAQ:ONCE) to Post Q3 2017 Earnings of ($1.89) Per Share, Wedbush Forecasts

Spark Therapeutics, Inc. (NASDAQ:ONCE) – Investment analysts at Wedbush decreased their Q3 2017 earnings estimates for Spark Therapeutics in a research note issued to investors on Wednesday. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings per share of ($1.89) for the quarter, down from their prior estimate of ($1.80). Wedbush has a “Underperform” rating and a $28.00 price target on the stock. Wedbush also issued estimates for Spark Therapeutics’ Q4 2017 earnings at ($1.96) EPS, FY2017 earnings at ($7.95) EPS, FY2018 earnings at ($3.01) EPS, FY2019 earnings at ($5.27) EPS, FY2020 earnings at ($3.52) EPS and FY2021 earnings at ($0.72) EPS.

Other equities research analysts also recently issued research reports about the stock. Jefferies Group LLC started coverage on shares of Spark Therapeutics in a research note on Monday, July 10th. They issued a “buy” rating and a $85.00 target price for the company. Cantor Fitzgerald set a $94.00 target price on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 9th. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $60.00 to $100.00 in a research note on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and issued a $92.00 target price (up previously from $70.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $92.00 target price (up previously from $77.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $82.27.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. (NASDAQ:ONCE) to Post Q3 2017 Earnings of ($1.89) Per Share, Wedbush Forecasts” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/08/19/spark-therapeutics-inc-nasdaqonce-to-post-q3-2017-earnings-of-1-89-per-share-wedbush-forecasts-updated.html.

Spark Therapeutics (NASDAQ ONCE) opened at 78.78 on Monday. The firm’s market cap is $2.44 billion. Spark Therapeutics has a 1-year low of $35.07 and a 1-year high of $80.89. The company’s 50 day moving average is $64.99 and its 200-day moving average is $59.11.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. During the same quarter in the prior year, the business earned ($1.04) EPS. Spark Therapeutics’s revenue was up 14.7% compared to the same quarter last year.

In related news, insider Katherine A. High sold 10,000 shares of the stock in a transaction on Monday, June 19th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the transaction, the insider now owns 220,000 shares in the company, valued at $13,200,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Barge Joseph La sold 5,000 shares of the stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $55.00, for a total transaction of $275,000.00. Following the transaction, the general counsel now owns 9,567 shares of the company’s stock, valued at approximately $526,185. The disclosure for this sale can be found here. Insiders have sold 314,310 shares of company stock valued at $21,866,838 in the last 90 days. 7.30% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Victory Capital Management Inc. boosted its position in shares of Spark Therapeutics by 11.4% in the first quarter. Victory Capital Management Inc. now owns 412,660 shares of the biotechnology company’s stock valued at $22,011,000 after buying an additional 42,388 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Spark Therapeutics by 7.8% in the first quarter. JPMorgan Chase & Co. now owns 1,549,093 shares of the biotechnology company’s stock valued at $82,628,000 after buying an additional 112,596 shares during the last quarter. TD Asset Management Inc. boosted its position in shares of Spark Therapeutics by 4.5% in the first quarter. TD Asset Management Inc. now owns 76,451 shares of the biotechnology company’s stock valued at $4,078,000 after buying an additional 3,300 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Spark Therapeutics by 10.9% in the first quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock valued at $5,923,000 after buying an additional 10,916 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Spark Therapeutics by 0.7% in the first quarter. American Century Companies Inc. now owns 488,519 shares of the biotechnology company’s stock valued at $26,058,000 after buying an additional 3,445 shares during the last quarter. Institutional investors and hedge funds own 88.95% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

What are top analysts saying about Spark Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spark Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit